Effect of Anti-TNF Antibodies on Clinical Response in Rheumatoid Arthritis Patients: A Meta-Analysis

Table 1

Characteristics of the included studies in this meta-analysis.

Study	Year	Area	TNFi	(%, female)	Age	Disease duration (ys)	MTX (%)	PRED (%)	Assay	Follow-up (months)	ADAb+	Outcome ()	ADAb−	Outcome ()
Bartelds  et al. [18]	2007	Netherlands	ADAL	121 (79)	53 ± 13	12 ± 10	79	34	RIA	6	21	9	100	76
Bender et al. [19]	2007	Germany	ADAL	15 (66.7)	55.9 ± 8.1	12.2 ± 8.2	66.7	100	ELISA	3	13	4	2	2
Chen  et al. [20]	2015	Taiwan	ADAL	36 (88.9)	52.9 ± 15.0	5.44 ± 2.42	88.9	NA	ELISA	6	8	2	28	28
									ELISA	12	10	3	26	23
									RIA	12	13	6	23	20
Finckh  et al. [21]	2010	Switzerland	INF	64 (76.6)	59.3 (NA)	13.8 (9.7)	81.3	46.9	ELISA	12	8	4	56	36
Garcês et al. [22]	2014	Portugal	Combine	105 (87)	54 ± 14	10.1 (4.6–12.6)	97	98	ELISA	12	18	4	87	54
Krieckaert  et al. [23]	2012	Netherlands	ADAL	204 (76)	54 ± 12	7 (3–16)	77	32	RIA	36	54	9	150	80
Krintel et al. [24]	2013	Denmark	INF	218 (80)	56 (21–86)	6 (0–56)	91	24	IMPACT	12	79	27	84	37
Pascual-Salcedo et al. [25]	2011	Finland	INF	85 (81.0)	53.8 ± 14.2	NA	81	74	ELISA	6	16	9	33	29
										12	7	4	24	23
										48	11	6	36	33
Radstake et al. [26]	2009	Netherlands	INF	35 (86.0)	57 ± 10	NA	100	29	RIA	3	14	3	21	18
										6	18	4	17	17
			ADAL	34 (79.0)	56 ± 10	NA	41	26	RIA	3	8	0	26	24
										6	10	0	24	24
Wolbink et al. [27]	2006	Netherlands	INF	51 (82.4)	56 ± 13	12 ± 9	86	0	ELISA	12	22	8	29	20

TNFi: tumor necrosis factor inhibitors; MTX: methotrexate; ADAL: adalimumab; INF: infliximab; ETN: etanercept; combine: INF/ETN/ADAL; PRED: prednisone; median (IQR, interquartile range); NA: not available; ELISA: enzyme-linked immunosorbent assay; RIA: radioimmunoassay; IMPACT: Immunological Multi-Parameter Chip Technology; ADAb+: anti-drug antibodies positive; ADAb−: anti-drug antibodies negative; outcome: good+ moderate EULAR responders.